FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines

The FDA has approved and granted emergency use authorization for updated mRNA COVID-19 vaccines for the 2024-2025 formula, targeting the Omicron variant KP.2 strain of SARS-CoV-2. This update aims to enhance protection against current variants, reducing the risk of severe outcomes like hospitalization and death. The vaccine is approved for individuals 12 and older, while emergency use authorization is given for individuals as young as six months.

These updated vaccines are part of the FDA's ongoing effort to adapt to the evolving virus. Officials have advised that vaccination remains a key preventive measure against COVID-19. Eligible individuals, including those previously vaccinated, can receive these updated doses to ensure stronger protection. The FDA reviewed manufacturing and nonclinical data to support this update and expects to continue assessing COVID-19 vaccine compositions annually, similar to seasonal flu vaccines.